Citations

Clear

3042 citation(s) found for "Kumar, S".

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes
Michaud, Marina E. , Ferguson, Katherine , Karagkouni, Dimitra , Network, MMRF Immune Atlas, Kumar, Shaji, Dhodapkar, Madhav V. , Vij, Ravi , Cho, Hearn, Avigan, David, Kourelis, Taxiarchis , Mulligan, George, Pilcher, William , Satpathy, Sarthak , Ohlstrom, Denis , Gonzalez‐Kozlova, Edgar , Acharya, Chaitanya R. , Song, Yizhe , Lagana, Alessandro , Kumar, Shaji , Parekh, Samir , Vlachos, Ioannis S. , Gnjatic, Sacha , Li, Ding , Lonial, Sagar , Nooka, Ajay K. , Bhasin, Manoj K

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2179-2179

10.1182/blood-2025-2179 Get It

Abstract Introduction: Multiple Myeloma (MM) is a complex hematologic malignancy, where patients often display one or more potentially high risk cytogenetic alterations associated with poor outcomes. Traditional high risk cytogenetics events in myeloma, such as NSD2 t(4;14) translocations, gain of 1q21, or deletion of 17p13, have often been studied in isolation, but emerging evidence suggests the combination of these high risk alterations has a greater negative prognostic impact than any on their own. This has been recently reflected in risk stratification guidelines from IMS and IMWG, which consider certain events, such as t(4;14), as high risk only in combination with gain of 1q21 or deletion of 1p32. Still, the mechanisms through which multi-hit high risk events disrupt the microenvironment and promote poor outcomes remains unclear. We hypothesize that myelomas with multiple high risk alterations remodel the immune environment to promote tumor progression and immune escape. Methods: To study the role of multi-hit high risk cytogenetics on the immune microenvironment, we analyzed CD138-bone marrow aspirate single-cell RNA sequencing (scRNAseq) data from 337 newly diagnosed MM patients from the MMRF CoMMpass study, generated as part of the Immune Atlas initiative. Cytogenetic alterations for these patients were derived from whole-genome and whole-exome sequencing of CD138+ bone marrow aspirates from the MMRF CoMMpass cohort. Patients were classified as multi-hit high-risk MM if they exhibited either (i) two high-risk cytogenetic events, including NSD2 t(4;14), MAF t(14;16), del(17p13), or (ii) one high-risk event with gain of 1q21. Results: Based on cytogenetic information, 33 patients in the Immune Atlas cohort were classified as 'multi-hit’ high-risk, while 34 patients had only a single high-risk alteration. These multi-hit high risk patents displayed significantly worse progression free survival compared to standard risk patients, adjusting for age, therapy, and ASCT (HR=2.34, p<7.2e-5), while single-hit patients showed a non-significant trend towards worse outcomes (HR=1.51, p=0.071). The most frequent multi-hit risk event in the cohort was NSD2 t(4;14) in combination with 1q21, observed in 23 patients. Compositional analysis of the immune populations in the scRNAseq data revealed that relative to both standard and single-hit high risk patients, multi-hit high risk patients displayed significant reductions in IFN-I stimulated CD4+ and CD8+ T cell populations, marked by decreased expression for antiviral response markers such as ISG15, XAF1, and IFI44L. Enrichment of inflammatory CD16+ non-classical monocytes was also observed. Further analysis of the most frequent multi-hit risk event, NSD2 with 1q21, revealed distinct enrichment of late-activated cytotoxic HLA+ CD8+T cells and cytotoxic CD4+.T cells. Neither alteration was observed in patients with single-hit NSD2 or 1q21. Further analysis on the interactions between high risk events revealed distinct transcriptomic profiles dependent on the high risk events involved, particularly in multi-hit events involving mutations or deletions of TP53 or gain of 1q21. Reduction in IFN-I signaling across various immune populations was primarily restricted to multi-hit risk events involving gain of 1q21. Conversely, patients with biallelic loss of TP53 displayed significant enrichment of these same IFN-I populations. Given this contrast in IFN-I signaling spanning multiple immune subtypes, we hypothesized that the malignant myeloma cells might similarly display altered IFN-I activity. Utilizing CD138+ myeloma bulk RNA sequencing data from CoMMpass, we found that IFN-I response scores strongly correlated between paired scRNA immune and bulk RNAseq tumor datasets (R2: 0.75, p=1.63e-32). Across 660 patients with bulk RNAseq and cytogenetic data, we confirmed significant reductions in IFN-I response scores in tumor cells in multi-hit high risk involving 1q21, and significant enrichment in those with complete loss of TP53 relative to standard-risk MM. Conclusions: Overall, we do observe that MM patients with multiple high risk cytogenetic alterations display distinct immunologic traits relative to standard risk or single-hit high risk patients in addition to significantly worse outcomes. Furthermore, we find variability in the immune alterations observed based on the cytogenetic events involved, further illustrating the heterogeneity in how MM shapes the immune microenvironment.
Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study
Gaballa, Mahmoud , Gregory, Tara, Costa, Luciano da Fontoura , Costello, Caitlin , Goldsmith, Scott , Hansen, Doris, Kumar, Shaji , Ramakrishnan, Aravind , Shaikh, Hira , Hong, Meiyue Grace, Wang, Steven , Cheung, Patricia , Dhakal, Binod , Shaikh, Hira , Richard, Shambavi , Chhabra, Saurabh , Anderson, Larry D. , Costa, Luciano, Hansen, Doris K. , Rajeeve, Sridevi , Battiwalla, Minoo , Nooka, Ajay K. , Hong, Meiyue Grace, Li, Liang , Dhakal, Binod

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 269-269

10.1182/blood-2025-269 Get It

Abstract Introduction: Multiple myeloma (MM) accounts for nearly 20% of all hematologic cancers in the US and remains a substantial clinical burden, with patients (pts) requiring multiple lines of therapy (LOT). While advances such as BCMA-directed CAR T-cell therapy have improved outcomes, challenges persist, including disease relapse, treatment toxicities (CRS, ICANS, and non-ICANS neurotoxicities), and access. AZD0120 (formerly GC012F) is a first-in-class autologous BCMA/CD19 dual-targeting CAR T-cell therapy using the FasTCAR rapid manufacturing platform that preserves the naive and central memory T-cell phenotypes with marked in vivo proliferative capacity. Phase 1 investigator-initiated trials in China demonstrated deep, durable responses and a favorable safety profile following single-infusion AZD0120 in newly diagnosed and relapsed/refractory MM (RRMM) (Du J, et al. EHA 2024 and ASCO 2023). Here, we report for the first time preliminary phase 1b results from DURGA-1, an ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of AZD0120 in pts with RRMM. Methods: This open-label, single-arm, US-based, multicenter study (NCT05850234) evaluated the safety/tolerability of 2 dose levels (DL) of AZD0120 in pts with RRMM along with preliminary efficacy. Eligible ptswere aged ≥18 y with RRMM (3+ prior LOT [pLOT] including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody), ECOG PS 0–1, and documented evidence of progressive disease. Exposure to BCMA-directed therapy ≥6 mo with best response of PR or better was permitted. Pts underwent lymphodepletion followed by a single infusion of AZD0120. Pts in DL1 received 1x105 cells/kg; DL2 received 3x105 cells/kg. Dose escalation and recommended phase 2 dose (RP2D) were determined by a safety review committee. Phase 1b primary objectives included safety/tolerability and RP2D determination; secondary objectives included efficacy, cellular kinetics (CK), and pharmacodynamics. Results: As of data cutoff (DCO) on 18 July 2025, a total of 25 pts received infusion of AZD0120 (n=12 DL1; n=13 DL2). The median age was 64 y (range 44–78), median pLOT was 4 (range 3–7), 72% were triple-class refractory, 20% had prior BCMA CAR T-cell therapy, 4% had prior teclistamab, 28% had high-risk cytogenetic features [del(13q), del(17p13), t(4;14), t(14;16), amp(1q)], and 8% had extramedullary plasmacytomas. The median time from apheresis to release was 14 d (range 10–30). Median time from apheresis to infusion was 28 d (range 19–44) with 5 pts receiving bridging therapy. Median follow-up was 1.4 mo (range 0–19.3). No dose-limiting toxicities were reported for either dose. The most common treatment-emergent AEs (TEAEs, any grade) were CRS (64%), neutrophil count decreased (56%), and anemia (32%). The most common grade ≥3 TEAEs were neutrophil count decreased (52%), lymphocyte count decreased (32%), and white blood cell count decreased (32%). CRS was reported in 75% of pts at DL1 (all grade 1) and 54% at DL2 (46% grade 1; 8% grade 2), with no cases of grade ≥3 CRS. Median time to CRS onset (DL1/DL2) was 9 d (range 2–11), with a median duration of 2 d (range 1–4); 12 pts (48%) received tocilizumab for CRS management and 12% received dexamethasone. No cases of ICANS, related non-ICANS neurotoxicity, IEC-colitis, or secondary primary malignancies have been reported. There have been no deaths. For efficacy-evaluable patients (n=15), ORR was 100% (33% sCR, 47% VGPR, 20% PR). CR rates in evaluable pts were 30% in DL1 (n=10) and 40% in DL2 (n=5); median time to response was 0.9 mo for both DLs (range 0.9–1.9 DL1; 0.6–1.8 DL2). All MRD-evaluable pts (n=5 DL1; n=3 DL2; DCO 01 July 2025) were MRD-negative by NGS at a sensitivity of 10-5. Three pts in DL1 with ≥12 mo follow-up maintained MRD negativity. Consistent with robust in vivo expansion, CK analysis from 16 evaluable pts (DCO 12 June 2025) demonstrated a median Tmax of 13 d post-infusion with a median Cmax of 85,266 copies/mg gDNA. Median persistence was 42 d (range 13–273). Updated clinical data with additional follow-up will be presented. Conclusion: Preliminary phase 1b results demonstrated AZD0120 was well tolerated, with a low incidence of serious AEs, no grade ≥3 CRS, and no ICANS. FasTCAR-manufactured AZD0120 had expectedin vivo expansion, which may have resulted in the predictable CRS profile. A single infusion of AZD0120 achieved early, deep responses with 100% MRD negativity from 4L+ triple-class‒exposed pts with RRMM.
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
Ali, Najla Al , Stein, Eytan M. , Brunner, Andrew M. , McMahon, Christine M. , Shallis, Rory M. , Hawkins, Hayley, Chandhok, Namrata S. , Logothetis, Constantine , Bidikian, Aram, Getz, Theodore, Harris, Amyah, Amaya, Maria , Ball, Somedeb , Grenet, Justin , Haferlach, Torsten , Maciejewski, Jaroslaw P. , Sallman, David A. , Al-Rabi, Kamal , Halahleh, Khalid , Pleyer, Lisa , Pappa, Vassiliki, Consagra, Angela , Al‐Kali, Aref , Stahl, Max, Bewersdorf, Jan Philipp , Kewan, Tariq Zuheir , Lanino, Luca , Wei, Wei , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Uy, Geoffrey L. , Urrutia, Samuel , Carraway, Hetty E. , Desai, Pinkal , Griffiths, Elizabeth A. , Zeidner, Joshua F. , Savona, Michael R. , Roboz, Gail J. , Rolles, Benjamin , Wang, Eunice S. , Xie, Zhuoer , Madanat, Yazan F. , Abaza, Yasmin , Campos, Jaclynn, Badar, Talha , Enjeti, Anoop Kumar , Hiwase, Devendra , Díez‐Campelo, María , Valcárcel, David , Haferlach, Claudia , Kotsianidis, Ιoannis , Pappa, Vasiliki , Santini, Valeria , Ogawa, Seishi , Nannya, Yasuhito , Stahl, Max, Porta, Matteo Giovanni Della , Komrokji, Rami S. , Zeidan, Amer M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 606-606

10.1182/blood-2025-606 Get It

Abstract Introduction: HMA monotherapy (HMAm) continues to be the standard of care for HR-MDS. While the addition of VEN to azacitidine (AZA) improved overall survival (OS) and complete remission (CR) rates among older pts with acute myeloid leukemia (AML) over AZA monotherapy, the recently completed phase III VERONA trial of AZA+/-VEN in HR-MDS failed to show an OS benefit for AZA/VEN over AZA monotherapy. Using the icMDS VALIDATE database, we compared outcomes of pts with HR-MDS treated with HMA or HMA/VEN as frontline therapy. Methods: The icMDS VALIDATE database includes over 4000 adult MDS pts who received HMA-based therapy from 32 international centers in 9 countries. For this analysis, we included pts with HR-MDS defined by International Prognostic Scoring System [IPSS] ≥1.5 or IPSS-revised [IPSS-R] ≥4 (at diagnosis or HMA initiation) and treated with HMAm or HMA/VEN as frontline therapy for HR-MDS. We assessed responses based on IWG 2023 criteria (Zeidan A et al, Blood 2023). Composite complete remission (cCR) was defined as CR+CRbi+CRuni+CRh+CRequivalent. We calculated OS from time of HMA initiation to date of death from any cause. Pts lost to follow-up were censored at the date they were last known to be alive. We used Kaplan-Meier methods to calculate OS and compared OS between different groups using the log-rank test. We used Cox and logistic regression models to adjust for baseline prognostic variables as appropriate. The study was funded by an independent grant from Abbvie. Results: A total of 1907 pts met eligibility and were included (1552 AZA, 221 decitabine, 134 HMA+VEN). 479 pts subsequently underwent allogeneic stem cell transplant (allo-SCT; 430 after HMAm [32.6%]; 49 after HMA/VEN [37.1%]). Our cohort was enriched for pts with adverse disease characteristics including complex karyotype (33.6%) and TP53 mutations (28.7%). Compared to pts treated with HMA/VEN, pts treated with HMAm were more likely to be male (p=0.012), have lower baseline platelet counts (p=0.037), peripheral blood (PB) blasts (p=0.004), or bone marrow blasts (p<0.001), and were less likely to have very high risk IPSS-M (p<0.001), TP53 mutations (p<0.001), or complex karyotype (p=0.020). In unadjusted analyses, the rate of cCR was significantly lower in HMAm treated pts compared to HMA/VEN treated pts (27.7% vs. 48.8%, p<0.001). However, CR rate was not significantly different (11.7% vs. 17.1% for HMAm and HMA/VEN, respectively, p=0.22). After adjusting for age, sex, and IPSS-M, pts treated with HMA/VEN were more likely to achieve cCR compared to HMAm with an odds ratio (OR) of 2.49 (95% CI: 1.56-3.96, p<0.001). When separated by TP53 mutation status, the OR for cCR for HMA/VEN vs HMAm was 4.17 (95%CI: 2.14-8.31; p<0.001) and 1.27 (95%CI: 0.54-2.86; p=0.57) for TP53 wild-type and TP53-mutant pts, respectively. In unadjusted analyses, median OS was 17.4 months for HMAm and 19.6 months for HMA+VEN, and OS did not differ significantly by treatment type (p=0.33). For HMAm treated pts, the OS rates at year 1, 2, 3 were 0.65 (95%CI: 0.63-0.67), 0.38 (95%CI: 0.36-0.40), and 0.27 (95%CI: 0.25-0.29), respectively. For HMA/VEN treated pts, the OS rates at year 1, 2, 3 were 0.64 (95%CI: 0.56-0.73), 0.45 (95%CI: 0.36-0.56), and 0.37 (95%CI: 0.27-0.51), respectively. In a multivariate analysis adjusting for age, sex, PB blast, IPSS-M and allo-SCT as a time-varying covariate, treatment with HMA/VEN vs HMAm did not significantly influence OS (hazard ratio (HR) of OS for HMA/VEN vs HMAm: 0.89, 95%CI: 0.69-1.13, p=0.33). When stratified by TP53 mutation status, HR of HMA/VEN vs. HMAm was favorable for TP53 wild-type (HR: 0.47; 95%CI: 0.29-0.74) but not TP53-mutant pts (HR=0.96; 95%CI: 0.66-1.41). Adjusting for other variables in the model, HR for pts who underwent vs. those who did not undergo allo-SCT were 0.65 (95% CI: 0.49-0.85) and 0.36 (95%CI: 0.24-0.53) in TP53 wild-type and mutant patients, respectively. Conclusion: In this large, international retrospective analysis from the icMDS VALIDATE database, HMA/VEN was associated with higher cCR rates—but not CR rates—compared to HMAm among pts with HR-MDS, though we observed no significant differences in OS. In our analysis, clinical benefit from the addition of VEN was most clear in TP53 wild-type pts, and allo-SCT was associated with improved OS regardless of baseline TP53 status. Our analysis was limited by the relatively small number of HMA/VEN-treated pts and heterogeneous real-world treatment patterns.
Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis
Huart, Antoine , Landau, Heather , Iida, Shinsuke , Motorna, Olga , Ishida, Tadao, Bhutani, Manisha, Cowan, Andrew J., Rosenberg, Tanya, Motte-Mohs, Ross La, Wang, Fan , Hoffman, David, Arriola, Emma, Yu, Jovian , Kumar, Shaji, Palladini, Giovanni, Chakraborty, Rajshekhar , Kastritis, Efstathios , Jaccard, Arnaud , Mollee, Peter , Ishida, Tadao , Kawano, Yawara , D’Souza, Anita , Hoffman, James, Talati, Chetasi , Motte‐Mohs, Ross La, Fei, Mingwei , Kumar, Shaji , Dispenzieri, Angela , Sanchorawala, Vaishali

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 692-692

10.1182/blood-2025-692 Get It

Abstract Background B-cell maturation antigen (BCMA)-targeting immunotherapies represent a promising class of treatment for the management of immunoglobulin light chain (AL) amyloidosis, a disease that is related to clonal plasma cells. Etentamig is a 2nd generation, off-the-shelf, fully human BMCA X CD3 bispecific antibody with bivalent BCMA domain and low CD3 affinity that targets both BCMA-expressing plasma cells and CD3-expressing T cells. Etentamig monotherapy is being studied in multiple myeloma (MM) in an ongoing phase 3 study (NCT06158841). Here, we report the first safety and efficacy results from M24-209, an open-label phase 1/2 study evaluating etentamig monotherapy in patients (pts) with relapsed/refractory (RR) AL amyloidosis from dose level 1 (DL1). Methods The phase 1 dose escalation (ESC) portion of the study (NCT06158854) with etentamig enrolled pts with RR AL amyloidosis with ≥1 prior lines of therapy (LOT), including a proteasome inhibitor and an anti-CD38 monoclonal antibody with no prior BCMA exposure. Eligible pts were required to have a difference in involved and uninvolved serum free light chain (dFLC) of ≥50 mg/L, and pts with Mayo Clinic 2004 cardiac risk stage IIIb with NT-proBNP ≥8500 pg/ml were excluded. Three dose groups were explored in dose ESC (etentamig dose levels [DL] 1, 2, and 3). In all cohorts, pts will receive up to 24 cycles of treatment and will be followed until disease progression. In dose ESC, the primary objectives are to determine safety/tolerability, pharmacokinetic/pharmacodynamic, and recommended phase 2 dose. The secondary objectives include evaluation of efficacy as measured by hematologic response and organ response. Responses are investigator assessed per consensus guidelines (Comenzo, et al. Leukemia. 2012. 26[11]:2317-25; Palladini G, et al. Amyloid. 2021 [Epub];28[1]:1-2). Results As of 17 July 2025, all DLs in dose ESC have been fully enrolled, and 12 pts have been treated with etentamig at DL1. Due to short follow-up, this initial report only includes data from DL1, with further follow-up data from ESC to be included at the time of presentation. Median duration of follow up in DL1 was 9.4 months (8.3–13.8) with 83% of pts continuing treatment. Median age for pts was 72 years (range, 56–85 years). Median number of prior LOT was 2 (range, 1–6), and median time from initial diagnosis was 3.6 years. Thirty-three percent have received a prior stem cell transplant and 50% previously received the regimen of daratumumab with cyclophosphamide, bortezomib, and dexamethasone in combination. Median dFLC at study baseline was 110. 5 mg/L (range, 56.6–617.5). At baseline, 83% of pts had cardiac involvement, 25% had renal involvement, and 8% had hepatic involvement. Eighty-three percent of pts had lambda AL amyloidosis. Treatment-emergent adverse events were reported in 100% (42% Grade ≥3) of pts at DL1. Cytokine release syndrome (CRS) occurred in 2 pts (17%, all Grade 1), with no instances of any grade immune effector cell-associated neurotoxicity syndrome (ICANS). CRS occurring after the first dose had median time to onset of 6.8 hours (range, 6.7–6.9). Grade ≥3 infections occurred in 1 pt (8%, all Grade 3). Grade ≥3 neutropenia also occurred in 1 pt (8%, all Grade 3), and no Grade ≥3 events of thrombocytopenia or anemia occurred. No Grade 5 events have occurred. Within the dose ESC DL1 cohort, the overall hematologic response rate was 100%, with all pts achieving ≥VGPR and 83% of pts achieving complete response (CR). The median time to CR was 0.9 months (0.3–9.3). The median duration of response has not yet been reached and 100% of pts remain in their best overall response by investigator assessment. To date, no pts have experienced hematologic progression on study. Cardiac response was observed in 30% of evaluable pts. Renal response was seen in 67% of evaluable pts. Conclusions In the DL1 cohort, etentamig showed a manageable safety profile in AL amyloidosis with low incidence and severity of CRS, no ICANS, and limited Grade ≥3 cytopenia events. Deep and rapid hematologic responses were observed with 100% ≥VGPR rate and 83% hematologic CR rate. Additional dose-level data will be presented at the time of the meeting. All pts remain in ongoing follow-up and evaluation, and the study will begin the dose expansion (EXP) portion after dose selection.
Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma
Ahsan, Aarif, Luo, Adam , Valdes, Cesar Rodriguez , Voorhees, Peter M. , Safah, Hana, McKay, John, Korde, Neha , Vij, Ravi, Kumar, Shaji , Doerr, Thomas, Pothacamury, Rajvineeth Kumar, Chyla, Brenda , D’Souza, Anita , Chung, Alfred , Tuchman, Sascha Alexander , Weisel, Katja C , Teipel, Raphael , Talati, Chetasi , Ross, Jeremy A.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5813-5813

10.1182/blood-2025-5813 Get It

Abstract Background: Clonotypic peptide detection by mass spectrometry (MS) leverages monoclonal protein (M-protein) de novo sequencing and peptide quantification to enable ultra-sensitive blood-based monitoring of multiple myeloma (MM) patient M-protein kinetics. Etentamig is a 2nd generation BCMA x CD3 bispecific antibody that has shown promising efficacy and a favorable safety profile in heavily pre-treated patients with relapsed or refractory (RR) MM (Journal of Clinical Oncology, 43;16:suppl.7527). In the current study, we explored the depth and kinetics of MS M-protein response to etentamig monotherapy in serum samples from Phase 1 M22-466 (NCT03933735) study patients. The correlation between blood-based MS M-protein levels and bone marrow minimal residual disease (MRD) negativity as determined by next generation sequencing (NGS) was also evaluated. Method: Clonotypic peptide MS using M-Insight (Sebia/Corgenix) was performed on serum samples from a subset of MRD evaluable patients enrolled into the Phase 1 (NCT03933735) clinical trial of etentamig monotherapy in patients with RRMM. Bone marrow MRD negativity (<10-5 and 10-6) analysis was determined by NGS (clonoSEQ, Adaptive Biotechnologies). Patient pre-treatment (Cycle [C] 1 Day [D] 1) serum samples were digested with proteolytic enzymes to permit sequencing of the M-protein heavy and light chain. Clonotypic peptides specific to the patient's complementarity-determining regions were selected for quantification by MS. Clonotypic peptide quantification by MS was performed on available tracking peripheral blood samples at C2D1, C3D1, C4D1, and C5D1 time points post etentamig monotherapy treatment. Results: Twenty patients who were MRD evaluable and treated with 40 mg and 60 mg doses of etentamig with available serum samples collected from C1D1–C5D1 time points were selected for M-Insight evaluation. Of the 20 patients, 16 (80%) had at least one clonotypic peptide identified prior to etentamig treatment that was utilized for tracking at subsequent time points. Rapid decline in MS M-protein levels was observed in patients treated with etentamig, which strongly correlated with the patients' best International Myeloma Working Group (IMWG) response. At C3D1 post etentamig treatment, patients with complete response (CR)/stringent CR (n=9) demonstrated a significant decline from MS M-protein levels (median: 1.8±0.9 g/dL at C1D1 to 0.03±0.2 g/dL at C3D1) (P<0.001). All evaluable subjects (n=16) had detectable MS M-protein at all time points (n=80). The lowest detectable M-protein level observed in the current dataset was 44 mg/dL (lower limit of quantitation of assay: 10 mg/dL). Subsequent analysis of differences in kinetics between MRD-negative (<10-5) (n=8) and MRD-positive (n=8) patients revealed a deeper reduction in M-protein levels for MRD-negative patients (median 0.02±0.2 g/dL at C3D1 compared with 0.4±0.3 g/dL at C3D1 for MRD-positive patients). Among the 8 patients who achieved MRD negativity at 10-5 threshold, 5 patients also achieved <10-6 threshold, and serum MS M-protein levels remained detectable in these patients (0.07±0.2 g/dL). Conclusions: Using MS-based clonotypic peptide detection, rapid and deep decline in serum M-protein levels was observed in RRMM patients treated with etentamig. Strong concordance was observed between MS M-protein levels and IMWG response, including in patients achieving MRD-negative CR at <10-5 and 10-6thresholds. Non-invasive and ultra-sensitive M-protein detection is feasible in MM and may serve as a key biomarker for enhancing the detection of residual disease in the future.
Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma
Janda, Guneet, Howe, Michael J. A., Shreve, Jacob , Dasari, Surendra , Abdallah, Nadine , Cook, Joselle , Kourelis, Taxiarchis , Hayman, Suzanne R. , Kumar, Shaji, Guzman, Emmanuel Contreras , Howe, Michael, Gonsalves, Wilson I. , Buadi, Francis K. , Cook, Joselle , Gertz, Morie A. , Fonseca, Rafaël , Dispenzieri, Angela , Rajkumar, S. Vincent , Thorpe, Matthew , Kumar, Shaji , Binder, Moritz

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 924-924

10.1182/blood-2025-924 Get It

Abstract Introduction: Suboptimal response to therapy, early disease relapse, and limited long-term survival remain critical challenges in a substantial number of patients with multiple myeloma (MM). While cross-sectional imaging studies are commonly obtained in clinical practice, only limited information is currently incorporated into risk stratification efforts and clinical decision making. Here, we investigate the use of novel image-based biomarkers to identify patients at high risk for adverse outcomes. Methods: We obtained the pretreatment 18F-FDG PET/CT scans of patients with newly diagnosed MM with available clinical and laboratory data seen at Mayo Clinic between 2006 and 2022. In this analysis, we included 637 patients with detectable metabolic tumor volume on their pretreatment scan. The native DICOM images were pre-processed and subjected to automated image segmentation using nnU-Net (nnU-Net v1.0, inference using a pre-trained hematologic malignancies model). Limitations of this automated segmentation approach include heterogeneity introduced by varying image quality, technical variability in PET reconstruction, and potential inclusion of non-neoplastic FDG-avid lesions in segmented regions. PyRadiomics was used to extract quantitative radiomics features for clinical prediction modeling. We evaluated the predictive power of tumor size-, shape-, and texture-related radiomics features for identifying high-risk disease (advanced ISS stage at diagnosis, the presence of high-risk FISH abnormalities, failure to achieve a stringent complete response [sCR] to first-line therapy by IWMG criteria, and early mortality). All radiomics features were quantile-normalized for downstream modeling. Forward and backward feature selection as well as testing for multicollinearity were used to remove redundant features. Results: Median age at diagnosis of the 637 myeloma patients was 64 years (range 22–90), and 387 patients (61%) were male. After a median follow-up of 4.4 years (95% CI 0.2–11.7), median overall survival (OS) was 7.3 years (95% CI 6.3–8.3). Increased total tumor volume (upper tertile vs lower tertiles), measured by the total tumor surface area, was associated with advanced ISS stage (III vs I+II; OR 1.73, 95% CI 1.24–2.42, p=0.001, n=637). Increased tumor density (dichotomized at the median), measured by the median gray level intensity (OR 1.93, 95% CI 1.94–3.12, p=0.007, n=303), and decreased tumor heterogeneity (lower tertile vs upper tertiles), measured by the variability of gray-level intensities (OR 1.88, 95% CI 1.49–3.12, p=0.012, n=303), were associated with the presence of high-risk cytogenetics. Both increased total tumor volume (4.9% increase per tertile, 95% CI 2.2–7.6, p<0.001, n=600) and tumor density (8.9% increase per tertile, 95% CI 4.5–13.3, p<0.001, n=600) were independently associated with more extensive bone marrow involvement at diagnosis. Increased tumor heterogeneity (upper tertiles vs lower tertile), as measured by rapid changes of gray level intensities, was associated with failure to achieve a stringent complete response to first-line therapy (OR 0.50, 95% CI 0.30–0.82, p=0.006, n=351). Increased tumor volume was associated with shorter OS (HR 1.35 per tertile, 95% CI 1.11–1.63, p=0.002, n=301), independent of age, sex, ISS stage, and the presence of high-risk cytogenetics. A simple additive score consisting of tertiles of total tumor volume, ISS stage, and plasma cell labeling index ≥2% identified patients at risk of mortality within 3 years of diagnosis (OR 2.00, 95% CI 1.40–2.85, p<0.001, n=126), with moderate discrimination (AUC=0.71). Sensitivity analysis demonstrated total tumor volume and texture as most predictive of overall survival in a random forest survival model (C-index 0.712, 95% CI 0.649–0.775) and tumor texture as most predictive of response to therapy in a random forest classification model (C-index 0.693, 95% CI 0.607–0.779). Conclusions: Automated image segmentation and radiomics feature extraction from 18F-FDG PET/CT scans produces biomarkers that capture disease stage, burden, and risk in newly diagnosed MM. Total tumor volume and heterogeneity are strongly associated with important disease characteristics and can be used to identify patients at high risk for therapeutic resistance, early mortality, and inferior long-term outcomes.
Altered bone marrow (BM) plasma amino acid (AA) composition reflects microenvironmental remodeling in patients with multiple myeloma (MM) compared to monoclonal gammopathy of unknown significance (MGUS)
Egan, Michael, Chawla, Yogesh, Dey, Puja, Jevremovic, Dragan, Hitosugi, Taro, Kumar, Shaji, Gonsalves, Wilson, Egan, Michael, Chawla, Yogesh, Dey, Puja, Jevremovic, Dragan, Hitosugi, Taro, Kumar, Shaji, Gonsalves, Wilson

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2149-2149

10.1182/blood-2025-2149 Get It

Abstract Altered Bone Marrow (BM) Plasma Amino Acid (AA) Composition Reflects Microenvironmental Remodeling in Patients with Multiple Myeloma (MM) compared to Monoclonal Gammopathy of Unknown Significance (MGUS) Michael Egan, Yogesh Chawla, Puja Dey, Dragan Jevremovic, Taro Hitosugi, Shaji Kumar and Wilson Gonsalves BACKGROUND: MYC overexpression, a hallmark of progression from MGUS to MM, drives metabolic reprogramming, including enhanced AA uptake and utilization. However, the contribution of AAs to disease progression from MGUS to MM remains poorly defined. In this study, we comprehensively profiled AA levels in the BM plasma of MGUS and MM patients to determine whether shifts in the availability of specific AAs reflect microenvironmental remodeling and evolving metabolic demands of malignant plasma cells (PCs). METHODS: AA profiles of BM plasma samples—reflective of the BM microenvironment—from two different cohorts of patients with either MGUS or MM (Cohort #1: 49 MGUS and 50 newly diagnosed MM (NDMM) and Cohort #2: 50 MGUS and 64 NDMM) were acquired using liquid chromatography (LC) coupled with tandem mass spectrometry (MS). Individual AA were quantified by MS using single-point quantification with isotopically labeled internal standards of AAs. Individual relative and quantitative AA data were analyzed for differences between the groups using the parametric t-test, and significance was defined as p < 0.05. We utilized a Pearson correlation coefficient method to determine the association of the percentage of clonal PCs in the BM to the levels of the AAs. The areas under the curve (AUC) of receiver operating characteristic (ROC) analyses were created on the web-based tool MetaboAnalyst 6.0 to determine the ability of quantitative AA levels to be utilized as a model to distinguish MGUS vs. MM. RESULTS: In BM plasma samples from cohort #1, using a global untargeted metabolite profiling, we identified 28 AAs and their metabolites out of the 1,089 known metabolites detected. A targeted quantification of these AAs was performed in the same samples to validate any observed differences between the groups. Both aspartate and glycine were found to be more abundant in NDMM compared to MGUS in both untargeted and targeted assays. In contrast,12 AAs (branched chain AAs: valine, leucine and isoleucine, aromatic AAs: tryptophan, kynurenine, tyrosine and phenylalanine; essential AAs: threonine and lysine; non-essential AAs: ornithine, citrulline and asparagine) were found to be less abundant in NDMM compared to MGUS. We then validated the presence of these differences using targeted quantification of AAs in the BM plasma samples from cohort #2. Aspartate was the only AA consistently found to be present at higher levels in NDMM vs. MGUS. Whereas, 8 AAs—threonine, valine, citrulline, tyrosine, tryptophan, isoleucine, phenylalanine, and kynurenine—were consistently lower in NDMM vs. MGUS. We observed a statistically significant positive correlation between the concentration of aspartate and the percentage of clonal PCs present in the BM (r = 0.56). In contrast, there were statistically significant negative correlations between the concentrations of all 8 AAs consistently lower in NDMM vs. MGUS and the percentage of clonal PCs in the BM: threonine (r = -0.41), valine (r = -0.35), citrulline (r = -0.37), tyrosine (r = -0.28), tryptophan (r = -0.31), isoleucine (r = -0.21), phenylalanine (r = -0.19), and kynurenine (r = -0.19). Using only the quantitative concentrations of the 9 AAs that were significantly different between NDMM and MGUS across both patient cohorts, we performed ROC analyses to develop predictive models distinguishing NDMM from MGUS. In cohort #1, the models yielded AUC values ranging from 0.738 to 0.785, while in cohort #2, AUC values ranged from 0.798 to 0.835, depending on the number of AAs included in the model. CONCLUSIONS: Several AAs are present at significantly different levels in the BM plasma of patients with NDMM compared to MGUS. These findings support the emerging role of AA availability, across a diverse set of AAs, in the pathogenesis and progression of MGUS to MM. Future studies are warranted to validate these observations and to determine whether alterations in the BM AA landscape can be leveraged for diagnostic or therapeutic strategies.
Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy
Foltz, Steven, Jayasinghe, Reyka, Network, MMRF Immune Atlas, Avigan, David, Parekh, Samir, Vij, Ravi, Kumar, Shaji, Kourelis, Taxiarchis, Lonial, Sagar, Cho, Hearn, Vlachos, Ioannis, Gnjatic, Sacha, Ding, Li, Bhasin, Manoj, Acharya, Chaitanya, Gout, Alexander, Mulligan, George, Foltz, Steven, Jayasinghe, Reyka, Network, MMRF Immune Atlas, Avigan, David, Parekh, Samir, Vij, Ravi, Kumar, Shaji, Kourelis, Taxiarchis, Lonial, Sagar, Cho, Hearn, Vlachos, Ioannis, Gnjatic, Sacha, Ding, Li, Bhasin, Manoj, Acharya, Chaitanya, Gout, Alexander, Mulligan, George

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4024-4024

10.1182/blood-2025-4024 Get It

Abstract Background: Recent clinical trials of immune checkpoint inhibitors (ICI) in multiple myeloma (MM) demonstrated the need to prioritize patients most likely to benefit from this type of therapy (Richard, et al., Nat. Cancer, 2024). Immune checkpoints in MM function through receptor-ligand (RL) interactions between CD8+ T cells and malignant plasma cells. However, there is a gap in our understanding of the immune checkpoint landscape in newly diagnosed MM (NDMM). To explore this, we mapped known immune checkpoint RL pairs in subjects enrolled in the CoMMpass Study (NCT01454297), a prospective, longitudinal observational trial. Methods Bone marrow aspirates from study participants were collected and separated into CD138 positive and CD138 negative fractions for comprehensive molecular characterization of the tumor (using bulk RNA sequencing and whole genome sequencing) and tumor immune microenvironment (using 3' single cell RNA sequencing (scRNA-seq)). 191 patients had paired bulk tumor and single cell immune expression profiles. To evaluate the co-expression of receptor-ligand pairs, we developed two approaches that combine gene expression values across single cell and bulk RNA-seq. The first approach uses joint percentiles to identify patients with high expression (top 75%) of both receptor and ligand (referred to as high-high). The second approach uses a rank-based interaction score to create a single value for each patient within a distribution defined for each receptor-ligand pair; patients with extreme values have high expression of both receptor and ligand. The two methods identified similar sets of patients with high co-expression of receptor and ligand. We then compared progression free survival (PFS) across receptor-ligand co-expression groups (high-high vs. others) and tested for other clinical associations. From a pre-defined list of 17 receptor-ligand pairs (Liu, et al., Exp. Hematol. Oncol., 2023), we focused on the following receptors (from CD8+ T cells) and ligands (from tumor plasma cells): PD-1 with PD-L1; LAG-3 with MHC-II; TIGIT with CD115; and TIM-3 with phosphatidylserine. Results Overall, 91 patients (91/191, 47.6%) showed high-high co-expression for at least 1 out of 17 receptor-ligand pairs, and 100 patients were high-high for no receptor-ligand pairs. Among patients with at least one high-high pair, there was a median of 2.0 high-high pairs (range: 1-11). Hierarchical clustering of high-high status and rank-based interaction score correlations showed that for a given receptor, patients often showed high-high co-expression across multiple related ligands. For TIM-3 (receptor, CD8+ T cells) and phosphatidylserine (ligand, tumor plasma cells), we identified 16 patients (16/191, 8.4%) with high-high co-expression and significantly worse PFS (median survival 485 vs. 1503 days, log-rank p-value 0.043). For PD-1-PD-L1, we identified 7 patients with high-high co-expression; for LAG-3-MHC-II, 12 patients (6.3%); and for TIGIT-CD115, 13 patients (6.8%). Conclusion ICI therapy remains an emerging area of study in MM. Here, we developed methods to explore immune checkpoint receptor-ligand co-expression from paired immune microenvironment and tumor cell populations. Our approach demonstrates the value of data integration across gene expression modalities, especially when standard sample collection methodologies segregate tumor and immune populations. Co-expression analysis may be one factor in prioritizing patients for immune checkpoint inhibitor therapy.
Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.
Zanwar, Saurabh , Goel, Utkarsh , Chao, Austin, Lien, Kyle, Mazzoni, Sandra , Khouri, Jack , Cassano, Raffaella Cassano , Addison, Daniel , Dominick, Anthony, Green, Kimberly M , Sborov, Douglas W. , Shetty, Sanath Kumar , Vazquez‐Martinez, Mariola , Avila, Gabriel De, Dixon, Ariel, Blue, Brandon , Freeman, Ciara L. , Ali, Hossam M. , Alomar, Mohammed , Alsina, Melissa , Shain, Kenneth H. , Davis, James A. , Davis, James A , Ali, Hossam M , Lee, Dae Hyun , Dima, Danai , Chao, Austin, Banerjee, Rahul , Williams, Louis S. , Anwer, Faiz , Lin, Yi , Cheng, Richard , Davis, James, Julian, Kelley , Shetty, Sanath, Locke, Frederick L. , Baz, Rachid , Puglianini, Omar Castañeda , Hansen, Doris K. , Grajales‐Cruz, Ariel , Raza, Shahzad

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4066-4066

10.1182/blood-2025-4066 Get It

Abstract Introduction: Teclistamab is the first FDA approved BCMA-directed bispecific antibody for the treatment of relapsed and refractory multiple myeloma (RRMM). With BCMA-targeting CAR-T therapies, cytokine release syndrome (CRS) is a risk factor for cardiotoxicity. Teclistamab was associated with fatal cardiovascular adverse events (CVAEs) in a recent US pharmacovigilance database analysis, but this analysis was limited by reporting bias. Therefore, the aim of our study is to conduct a multicenter study to define the real-world incidence of CVAEs in RRMM patients treated with teclistamab. Method We performed a retrospective multi-center cohort study of patients receiving teclistamab at 5 medical centers. Baseline oncologic and cardiovascular characteristics (including vital sign and echocardiographic data) were collected. Baseline cardiovascular disease (CVD) was defined as presence of coronary artery disease, congestive heart failure, severe or symptomatic valvular heart disease, or stroke at baseline. CVAE was collected and categorized based on CTCAE v5.0 by each institution. Major adverse cardiovascular event (MACE) was a composite outcome with any of the following: congestive heart failure, asymptomatic cardiomyopathy (interval LVEF drop >10% to resultant LVEF less than 50%), coronary artery disease requiring intervention, stroke or cardiovascular death. Arrhythmia was a composite outcome with any of the following: atrial tachyarrhythmia, ventricular tachyarrhythmia or bradyarrhythmia. Median follow-up was calculated through reverse Kaplan-Meier method. Multivariable Cox regression analysis was used to define the relation between MACE and survival. Cause of death was categorized as myeloma-related death or non-myeloma-related deaths (i.e. CRS, infection or cardiovascular death). Cause-specific Cox regression was performed to define relationship between MACE and cause of death. Results In a cohort of 219 patients treated with teclistamab with median follow-up of 20.1 months, 7.3% (N=16) developed MACE, 7.3% (N=16) developed arrhythmia and 12.8% (N=28) developing any MACE or arrhythmia. MACE occurred at a median of 4.5 days (IQR 2.25-15.75 days) after teclistamab step-up. The incidence of MACE was 16.4% in patients with baseline CVD versus 2.7% in those without baseline CVD (p<0.001). Patients who developed MACE had inferior ECOG performance status (PS) (PS >=2: 62.5% vs. 27.7%; p=0.008). Additionally, baseline hemoglobin level (9 vs 10g/dL; p=0.072) was numerically lower in MACE, compared to no MACE. There was no difference in age, sex, bone marrow (BM) plasma cell burden, ferritin, C-reactive protein or LDH levels between MACE vs. no MACE group. Patients who developed MACE had lower baseline diastolic blood pressure (67.7 vs 73.8mmHg; p=0.041) and numerically lower LVEF (51.4 vs 59.3%; p=0.059; baseline echocardiogram performed in 86% of all cohort). Patients who developed MACE had similar incidences of CRS (Grade >=2: 25.0 vs 16.7%; p=0.620) and immune effector cell-associated neurotoxicity (ICANS) grade 2 or higher (12.5 vs 7.5%; p=0.812). In multivariable Cox regression analysis, MACE was independently associated with inferior overall survival (HR 2.72; 95% CI 1.41-5.25; p=0.003), after adjusting for baseline CVD, age, high BM burden, extramedullary disease, and plasma cell leukemia. In cause-specific multivariable Cox regression analysis, MACE was independently associated with non-myeloma-related death (HR: 10.77 95% CI 4.39- 26.41; p<0.001) but not with myeloma-related death (1.54; 95% CI 0.64- 3.70; p=0.336). Conclusion In conclusion, in this large, real-world multicenter study, we observed that MACE occurred in over 7% of patients following teclistamab for RRMM, typically within 2 weeks of initiation. MACE was significantly associated with increased non-myeloma-related mortality. In contrast to CAR-T therapy, CRS or ICANS were not associated with MACE, whereas majority of patients who developed MACE had ECOG PS >=2 or baseline cardiovascular disease. More studies are necessary to define mechanisms and strategies to reduce these MACE and improve survival. Patients with baseline cardiovascular disease or poor performance status may benefit from cardiovascular optimization before and during teclistamab therapy.
Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations
Zanwar, Saurabh , Hansen, Doris, Goel, Utkarsh , Afrough, Aimaz , Rana, Masooma , Davis, James A. , Sborov, Douglas W. , Bal, Susan, Shune, Leyla , Ferreri, Christopher J. , Biran, Noa , Hassan, Hamza , Khouri, Jack , Corraes, Andre De Menezes Silva , Cassano, Raffaella Cassano , Liang, Emily C. , Ali, Hossam M. , Varga, Cindy , Richards, Tiffany, Hosoya, Hitomi , Gaballa, Mahmoud , Green, Kimberly , Sannareddy, Aishwarya , Anderson, Larry J., Alsina, Melissa , Mikkilineni, Lekha , Krishnan, Amrita , Voorhees, Peter M. , Kumar, Shaji , Sidana, Surbhi , Patel, Krina K. , Dhakal, Binod , Lin, Yi, Costa, Luciano da Fontoura , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Ali, Hossam M , Pasvolsky, Oren , Hansen, Doris K. , Portuguese, Andrew J. , Bal, Susan , Janakiram, Murali , Biran, Noa , Herr, Megan M. , Hassan, Hamza, Grajales‐Cruz, Ariel , Kort, Jeries , Atrash, Shebli , Puglianini, Omar Castañeda , Baz, Rachid , Zolotov, Eli , Dillard, Christen , Fortuna, Gliceida Galarza , Lee, Lisa K. , Julian, Kelley , Green, Kimberly, Anderson, Larry, Raza, Shahzad , Dima, Danai , Anwer, Faiz , Banerjee, Rahul , Locke, Frederick L. , Dhakal, Binod

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4069-4069

10.1182/blood-2025-4069 Get It

Abstract Introduction: Bispecific T-cell engagers (TCE) targeting BCMA (teclistamab, elranatamab) and GPRC5D (talquetamab) are important therapeutic options in relapsed/refractory MM (RRMM). However, data on the independent prognostic impact of individual cytogenetic abnormalities and functional high-risk MM on outcomes with TCEs remains limited. Methods We included RRMM patients treated with BCMA TCEs (teclistamab, elranatamab) and talquetamab across 15 centers in the US. Patients where TCEs were used only as bridging therapy to CAR-T were excluded. High-risk cytogenetic abnormalities (HRCA) included del(17p), t(4;14), t(14;16), 1q gain/amplification (1q21+), del(1p) before initiation of TCE. Functional high-risk disease (FHRMM) was defined as PFS <18 months with frontline therapy. Extramedullary disease (EMD) included visceral or soft tissue disease and excluded paraskeletal disease. Progression-free survival (PFS) was estimated from TCE initiation using the Kaplan–Meier method and compared using the log-rank test. Univariate and multivariable Cox proportional hazards models were used to identify predictors of PFS in the entire cohort and the subcohorts of BCMA TCEs and talquetamab (Talq). Results We analyzed 943 treatment initiations with TCEs in RRMM, comprising 577 BCMA-directed TCEs [teclistamab (n=436) and elranatamab (n=141)] and 366 talquetamab initiations. The median follow-up from TCE initiation was 13.4 months (95% CI: 12.5–14.2) and median age was 68 years (interquartile range 61-75 years). Two ore more HRCAs were noted in 30% of the cohort (34% in Talq vs. 28% in BCMA TCEs, p=0.04), EMD was present in 21% of patients (26% in Talq vs. 18% in BCMA TCEs, p=0.002), and 45.5% of patients had FHRMM (47% in Talq vs. 45% in BCMA TCE, p=0.54). The median prior lines of therapy was 6 (interquartile range: 5-8), with 92% being triple-class refractory (TCR); 60% received prior BCMA-directed therapy (85% in Talq vs. 45% in BCMA TCE, p<0.0001) and 45% had prior CAR-T in 45% (57% in Talq vs. 37% in BCMA TCE, p<0.001). The best overall response rate (ORR) was 67.1 % for the entire cohort (66.4% for BCMA cohort and 68.2% for Talq), with 32.5% patients achieving a ≥ complete response. The median PFS was 7.7 months (95% CI: 6.7–8.6) for the entire cohort, with a median PFS of 10.1 months (95% CI: 7.5-13.4) for teclistamab and 10.1 months (95% CI: 3.9-NR) for elranatamab. In the more heavily pretreated talq cohort, the median PFS was 6.4 months (95% CI: 5.1-7.5). In a univariate analysis (UVA), several HRCAs were associated with inferior PFS−del(17p) (HR 1.59), t(4;14) (HR 1.43), del(1p) (HR 1.54), and ≥2 HRCAs (HR 1.64), all p<0.01. Apart from HRCAs, adverse disease characteristics included FHRMM (HR 1.20) and EMD (HR 1.46); all p<0.05. Among laboratory markers, hemoglobin <9 g/dL (HR 2.10), platelet count <75 ×10⁹/L (HR 1.96), and elevated ferritin (≥600 ng/mL; HR 2.17) (all p<0.01) were prognostic for PFS. ECOG ≥2 (HR 1.62), prior BCMA-directed therapy (HR 1.56), and prior CAR-T (HR 1.44) (all p<0.001) were also associated with inferior PFS. In a multivariable analysis (MVA), prior BCMA therapy (HR 1.72, p<0.0001), ferritin >600 ng/mL (HR 1.68, p<0.0001), hemoglobin <9 g/dL (HR 1.53, p=0.001), ECOG PS ≥2 (HR 1.52, p=0.0009), del(17p) (HR 1.44, p=0.0034) and FHRMM (HR 1.26, p=0.047), were associated with inferior PFS. Within the talq cohort (n=366), EMD (HR 1.64), del(17p) (HR 1.42), del(1p) (HR 1.54), FHRMM (HR 1.34), ECOG ≥2 (HR 1.56), ferritin >600 (HR 1.88), hemoglobin <9 g/dL (HR 1.6), platelet count <75 ×10⁹/L (HR 1.36) and leukopenia <0.25 x 10⁹/L (HR 1.52) were adverse prognostic markers on UVA. A MVA confirmed the independent impact of ferritin >600 ng/mL (HR: 1.77), ECOG ≥2 (HR 1.61) and functional high-risk status (HR 1.52) on PFS, whereas del(17p) and EMD were trending toward significance. Within the BCMA TCE cohort (n=577), prior BCMA therapy (HR 1.9), ferritin >600 (HR 1.79), ECOG ≥2 (HR 1.55), Hb <9 g/dL (HR 1.54), and del(17p) (HR 1.52) were independently associated with inferior PFS on a MVA.Conclusions: In this large real-world cohort of TCE, outcomes varied by fitness, disease biology, and treatment history. The ECOG PS, elevated ferritin, functional high-risk status and del(17p) were consistently associated with inferior PFS. Prior BCMA exposure was an independent risk factor for inferior PFS in the BCMA TCE cohort, but not with talquetamab.